MedTrace Logo

Kinetic Study of Lp(a) and PCSK9 in Humans

NCT04247048 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-02-23

No results posted yet for this study

Summary

The aim is to study the relationship between lipoprotein(a) \[Lp(a)\] and PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9) in humans with a kinetic study of lipoproteins in patients with dramatic increase of Lp(a) and controls.

Conditions

  • Cholesterol; Metabolic Disorder
  • Lipoproteinemia

Interventions

OTHER

infusion of tracer [5,5,5-2H3] -L-leucine

A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.

Sponsors & Collaborators

  • Centre de Recherche en Nutrition Humaine Ouest (CRNH)

    collaborator UNKNOWN

  • Nantes University Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-31
Primary Completion
2021-12-23
Completion
2021-12-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04247048 on ClinicalTrials.gov